Diagnostic Performance of the Resistance Index (RI) for the Assessment of Cerebral Vasoreactivity in Transcranial Doppler

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Mar 10, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new test called the Resistance Index (RI) to help doctors assess brain blood flow in patients with significant narrowing (stenosis) or blockage (occlusion) of the carotid artery. The aim is to identify patients who may be at high risk for stroke and could benefit from a more complex test that measures how well their brain blood vessels respond to changes in blood flow. By using the RI, which is simpler and quicker, doctors hope to efficiently determine which patients truly need the more detailed testing, saving time and resources.

To participate in this study, patients must be adults with a significant narrowing (70% or more) of the carotid artery or a blockage of atherosclerotic origin, and they should be asymptomatic or have experienced minor symptoms. Participants need to give their consent to join and must be part of a health insurance plan. Those who are pregnant, unable to provide consent, or have certain medical conditions that prevent them from participating will not be eligible. If you join the trial, you can expect to undergo some tests that will help doctors understand your brain's blood flow better, which could lead to more personalized treatment options for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient must have given their free and informed consent and signed the consent form
• • The patient must be a member or beneficiary of a health insurance plan
• • Stenosis ≥ 70% in diameter reduction in NASCET equivalent or occlusion of atheromatous origin of the cervical internal carotid artery, asymptomatic or symptomatic.
• • Presence of a temporal window sufficient to record the homolateral and contralateral middle cerebral artery.
• • Patient of legal age with free and informed consent.
• • Patient who has signed the consent form.
• • Patient affiliated or beneficiary of a health insurance plan.
• Exclusion Criteria:
• • The subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
• • The subject refuses to sign the consent
• • It is impossible to give the subject informed information
• • The patient is under safeguard of justice or state guardianship
• • Contraindication to Acetazolamide Diamox® injection.
• • Absence of temporal acoustic window (non visualization of the cerebral parenchyma, no recordable intracranial vessel).
• • Insufficient temporal window (visualizable brain parenchyma, no recordable MCA)
• • Internal or common carotid artery stenosis ≥70% or occlusion, contralateral to the primary lesion.
• • Stenosis ≥50% of the middle cerebral artery homolateral or contralateral to the cervical lesion.
• • Patient in exclusion period determined by another study.
• • Patient under court protection, guardianship, or conservatorship.
• • Patient refusing to sign the consent form.
• • Patient unable to express his or her will (dementia, disturbed consciousness, etc.)
• • Patient for whom it is impossible to give informed information for health reasons or because of a language barrier.
• • Pregnant, parturient, or breastfeeding patient.